The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Lincoln Minerals (LML) has announced Grace Tsui has resigned from her role as Managing Director
  •  Lincoln Minerals is an Australian graphite developer, exploring the Eyre Peninsula in South Australia where it holds key mineral licences
  • The Lincoln board will assume the responsibility of managing the company until a replacement Manging Director is appointed
  • Lincoln Minerals is in the grey, trading at 0.8 cents per share

Lincoln Minerals (LML) has announced Managing Director, Grace Tsui, has resigned from her position.

Lincoln Minerals is an Australian graphite developer, exploring the Eyre Peninsula in South Australia where the company holds key mineral licences.

Lincoln is focussed on enhancing the company’s graphite resources via its flagship Kookaburra Gully Graphite Project.

The play is situated 35 kilometres north of southern Eyre Peninsula’s main hub, Port Lincoln, where they have defined mineral resources including graphite, magnetite and hematite resources.

Grace Tsui is leaving the company to pursue other business interests.

The Lincoln board will assume the responsibility of managing the company until a replacement Managing Director is appointed.

Until that time, Grace will remain on the board.

Lincoln Minerals is in the grey, trading at 0.8 cents per share at 1:15 pm AEDT.

LML by the numbers
More From The Market Herald
The Market Herald Video

TMH Market Update: ASX200 down 0.3pc as energy sector falters

The ASX200 is down just over a third of a per cent. Most sectors are in…

Invictus Energy announces gas discovery in Mukuyu-2 well, Zimbabwe

Invictus Energy (ASX:IVZ) has been trading higher today after announcing a gas discovery in the Mukuyu-2…

BBX Minerals extends Ema REE mineralisation to 7km x 6km

BBX Minerals (ASX:BBX) has extended the REE mineralisation at Ema in the Apuí region of Brazil…

Cynata Therapeutics receives approval to launch phase two trial of CYP-001 in Turkey

Cell therapy company, Cynata Therapeutics (ASX:CYP) has received regulatory and ethics approval to commence a phase…